Detection of clinically relevant T-cell receptors requires tailored approaches, and TCR gene therapy carries inherent risks

Köksal and Wälchli (1) highlight important issues regarding the isolation of clinically relevant T-cell receptors (TCRs) and their use in TCR gene therapy for the treatment of cancer. Although we see overlap in the opinions held by them and ours, we would like to take this opportunity to resolve some misrepresentations of our data and methodology (2). We will also attempt to show that the discussion concerning the safety of TCR gene therapy is more nuanced than described by Köksal and Wälchli.